H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Aadi Bioscience (AADI – Research Report) today and set a price target of $48.00. The company’s shares closed last Monday at $15.36, close to its 52-week low of $11.00.
According to TipRanks.com, Burns ‘ ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -26.1% and a 22.1% success rate. Burns covers the Healthcare sector, focusing on stocks such as Turning Point Therapeutics, Black Diamond Therapeutics, and Springworks Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Aadi Bioscience with a $39.00 average price target.
The company has a one-year high of $49.80 and a one-year low of $11.00. Currently, Aadi Bioscience has an average volume of 101.4K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aerpio Pharmaceuticals Inc. is a biopharmaceutical company, which engages in the research and development of treatments for ocular diseases. Its product candidate is AKB-9778, a small molecule activator of the Tie2 pathway, which completed the Phase 2a clinical trial for the treatment of diabetic retinopathy. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications; and AKB-4924, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed a single ascending dose clinical trial for the treatment of inflammatory bowel disease. The company was founded by Joseph H. Garder on November 17, 2011 and is headquartered in Cincinnati, OH.
Read More on AADI:
- H.C. Wainwright Thinks Urogen Pharma’s Stock is Going to Recover
- H.C. Wainwright Thinks Chromadex’s Stock is Going to Recover
- H.C. Wainwright Thinks AIkido Pharma’s Stock is Going to Recover
- Wedbush Maintains a Hold Rating on NY Community (NYCB)
- Analysts Are Bullish on Top Healthcare Stocks: Veru (VERU), Achieve Life Sciences (ACHV)